Drug therapy: Multidisciplinary management of lung cancer

被引：698

作者：

Spira, A ^{[1
]}

Ettinger, DS ^{[1
]}

机构：

[1] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2004年 / 350卷 / 04期

关键词：

D O I：

10.1056/NEJMra035536

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：379 / 392

页数：14

共 126 条

[1]

AISNER J, 1983, CANCER TREAT REP, V67, P37

[2]

ALBERTI W, 1995, BRIT MED J, V311, P899

[3]

[Anonymous], 1995, Eur J Surg Oncol, V21, P69

[4]

[Anonymous], P AM SOC CLIN ONCOL

[5]

[Anonymous], P AM SOC CLIN ONCOL

[6]

[Anonymous], P AM SOC CLIN ONCOL

[7] Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease [J].

Ardizzoni, A ;

Hansen, H ;

Dombernowsky, P ;

Gamucci, T ;

Kaplan, S ;

Postmus, P ;

Giaccone, G ;

Schaefer, B ;

Wanders, J ;

Verweij, J .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) :2090-2096

[8]

Argiris A, 2001, CANCER J, V7, P437

[9] BRONCHOGENIC-CARCINOMA - INCIDENCE OF METASTASES TO NORMAL SIZED LYMPH-NODES [J].

ARITA, T ;

KURAMITSU, T ;

KAWAMURA, M ;

MATSUMOTO, T ;

MATSUNAGA, N ;

SUGI, K ;

ESATO, K .

THORAX, 1995, 50 (12) :1267-1269

[10]

ARRIAGADA R, 1994, ANTICANCER RES, V14, P333

← 1 2 3 4 5 6 7 8 9 10 →